4.6 Review

Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes

期刊

DIABETES & METABOLISM
卷 47, 期 6, 页码 -

出版社

MASSON EDITEUR
DOI: 10.1016/j.diabet.2021.101275

关键词

DPP-4 inhibitors; Elderly; Personalised therapy; Safety; SGLT2 inhibitors; Type 2 diabetes mellitus

向作者/读者索取更多资源

DPP-4 inhibitors and SGLT2 inhibitors provide new options for oral management of type 2 diabetes in the elderly, with similar glucose-lowering efficacy but potentially different tolerance and safety profiles, favoring DPP-4 inhibitors.
Dipeptidyl peptidase-4 inhibitors (DPP-4is) and sodium-glucose cotransporter type 2 inhibitors (SGLT2is) offer new options for the oral management of type 2 diabetes mellitus (T2DM), with the advantage in the elderly population to be devoid of a high risk of hypoglycaemia. SGLT2is have also shown benefits regarding cardiovascular (heart failure) and renal protection, including in patients with T2DM aged >= 65 years while DPP-4is have only proved cardiovascular and renal safety without superi-ority compared with placebo. The glucose-lowering efficacy of the two pharmacological classes is almost similar including in older patients with T2DM. However, the tolerance and safety profile may be highly different and overall more favourable with DPP-4is than with SGLT2is. Some adverse events have been reported with SGLT2is which may be more prevalent or severe in older patients than in younger patients. The present comprehensive review focuses on the benefit/risk balance in the elderly population with T2DM by comparing the profile of DPP-4is and SGLT2is regarding the following poten-tial issues: metabolic disorders (hypoglycaemia and diabetic ketoacidosis); cardiac and vascular issues (atheromatous cardiovascular disease, heart failure, volume reduction hypotension, and lower limb amputations); renal endpoints including acute renal injury; risk of infections; digestive disorders; bone and skin adverse events; and cancer risk. Both DPP-4is and SGLT2is have their own advantages and disadvantages. Personalised treatment is recommended based upon the efficacy /safety profile of each drug class and individual patient characteristics that may be markedly different among the heteroge-neous population of older individuals with T2DM. (c) 2021 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据